COMMUNIQUÉS West-GlobeNewswire

Emblem Corp. Reports Strong Third Quarter 2018 Financial Results
20/11/2018
Revenues increase 281% over the quarter ended September 30, 2017 and 50% over Q2 2018 TORONTO, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Emblem Corp. (TSXV: EMC, OTCQX: EMMBF) (“Emblem” or the “Company”), a licensed producer of [...]
Tetra Bio-Pharma Enters into Binding Proposal with Quantum Pharma Inc.
20/11/2018
Company takes a significant step forward to become a fully integrated drug development company ORLEANS, Ontario, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (“ Tetra ” or “ TBP ”), (TSX VENTURE: TBP) (OTCQB [...]
New TRU NIAGEN® Stick Packs Target New Audiences and Consumer Needs
20/11/2018
ChromaDex expands TRU NIAGEN® product line, offering single-serving stick packs for on-the-go consumers and athletes LOS ANGELES, Nov. 20, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today the [...]
Maple Leaf Green World Inc. Enters into a Letter of Intent to Acquire A Production License in Clark County, Nevada
20/11/2018
CALGARY, Alberta, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Maple Leaf Green World Inc. (“ Maple Leaf ” or the “ Company ”) ( NEO: MGW, OTCQX: MGWFF ) is pleased to announce that it has expanded its interests in Nevada by [...]
Announcement from major shareholder
20/11/2018
November 20, 2018 Announcement no. 23 Announcement from major shareholder Today, and pursuant to sections 30 and 38 of the Danish Capital Markets Act, BioPorto A/S has received notice that Media-Invest Danmark A/S holds [...]
Arvinas To Present at the 30th Annual Piper Jaffray Healthcare Conference
20/11/2018
NEW HAVEN, Conn., Nov. 20, 2018 (GLOBE NEWSWIRE) -- Arvinas Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on protein degradation, today announced that John G. Houston, Ph.D., President [...]
Amarin to Present at the Evercore ISI HealthCONx Conference
20/11/2018
BEDMINSTER, N.J., and DUBLIN, Ireland, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve [...]
Completion of share capital increase
20/11/2018
November 20, 2018 Announcement no. 22 Completion of share capital increase The Board of Directors of BioPorto A/S (BioPorto) decided on November 11, 2018 to partially exercise the authorization in article 16b of the [...]
Aslan Pharmaceuticals to Participate in 30th Annual Piper Jaffray Healthcare Conference
20/11/2018
SINGAPORE, Nov. 20, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in [...]
Transactions in relation to share buyback program
20/11/2018
Acting under its share buyback authorization, the GN Store Nord Board of Directors initiated a share buyback program on May 2, 2018, in accordance with article 5 of the regulation (EU) no. 596/2014 of 16 April 2014 on [...]
Orphazyme to present at Redeye Life Science Day
20/11/2018
Orphazyme A/S Investor news No. 13/2018 Company Registration No. 32266355 Copenhagen, November 20, 2018 – Orphazyme A/S , a biopharmaceutical company dedicated to developing treatments for patients living with rare [...]
FIT Biotech Oy: FIT Biotech in Sijoitus Invest event on 22 November 2018
20/11/2018
FIT Biotech Oy Press release 20.11.2018 at 09:30 EET FIT Biotech in Sijoitus Invest event on 22 November 2018 FIT Biotech ("Company", FITBIO: FN Finland) is participating in Sijoitus Invest, an annual event for private [...]
New U.S. patent related to Oasmia Pharmaceutical’s nanotechnology platform XR17 has been granted
20/11/2018
Oasmia Pharmaceutical AB (Nasdaq: OASM) announces that the United States Patent and Trademark Office (USPTO) has issued a notification of allowance of a patent for its unique nanotech method to produce novel [...]
OSE Immunotherapeutics and Oncology Physician Network GERCOR Announce Initiation of Phase 2 Clinical Trial to Evaluate Tedopi® in Combination with Opdivo® (nivolumab) in Pancreatic Cancer
20/11/2018
The trial, sponsored and conducted by oncology group GERCOR, will be supported by Bristol-Myers Squibb and OSE Immunotherapeutics Pancreatic cancer is an indication with significant unmet need and represents an [...]
Rule 2.9 Announcement
20/11/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 20 November 2018 [...]
DBV Technologies Presents Data at ACAAI 2018 on Investigational Viaskin Peanut for the Treatment of Peanut-Allergic Children
20/11/2018
Montrouge, France, November 20, 2018 DBV Technologies Presents Data at ACAAI 2018 on Investigational Viaskin Peanut for the Treatment of Peanut-Allergic Children Three oral presentations highlighted analyses from the [...]
DBV Technologies présente à l'ACAAI 2018 des données relatives à Viaskin Peanut, un médicament expérimental pour le traitement de l'allergie à l'arachide chez les enfants
20/11/2018
Montrouge, France, le 20 Novembre (07h30 CET), 2018 DBV Technologies présente à l'ACAAI 2018 des données relatives à Viaskin Peanut, un médicament expérimental pour le traitement de l'allergie à l'arachide chez les [...]
Innate Pharma appoints experts to new Strategic Advisory Board
20/11/2018
Innate PHARMA APPOINTS EXPERTS TO NEW strategic advisory board Marseille, France, November 20, 2018, 07:00 AM CEST Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH) today announced the appointment of [...]
Innate Pharma nomme son nouveau Conseil Stratégique composé d'experts en immuno-oncologie
20/11/2018
Innate PHARMA nomme son nouveau conseil strategique COMPOSÉ D'EXPERTS EN IMMUNO-ONCOLOGIE Marseille, France, le 20 novembre 2018, 07h00 Innate Pharma SA (la « Société » - Euronext Paris : FR0010331421 - IPH) a annoncé [...]

Pages